Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H22O8 |
Molecular Weight | 414.4061 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COc1cc(cc(c1OC)OC)[C@]2([H])c3cc4c(cc3[C@@]([H])([C@@]5([H])COC(=O)[C@@]52[H])O)OCO4
InChI
InChIKey=YJGVMLPVUAXIQN-XVVDYKMHSA-N
InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1
DescriptionSources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=affc1058-7355-4486-8b65-378fea6f9454Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=9562603
http://products.sanofi.ca/en/condyline.pdf
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=affc1058-7355-4486-8b65-378fea6f9454
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=9562603
http://products.sanofi.ca/en/condyline.pdf
Podofilox ((abbreviated as PPT), otherwise known as podofilox) is an antimitotic drug which can be chemically synthesized or purified from the plant families Coniferae and Berberidaceae (e.g. species of Juniperus and Podophyllum). Podofilox 0.5% solution is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts. Treatment of genital warts with podofilox results in necrosis of visible wart tissue. The exact mechanism of action is unknown, but is believed to exert its antimitotic effect by binding to tubulin, at a site close to but not identical to the binding site of colchicine; it is thought that this antimitotic effect causes necrosis of wart tissue, the observed clinical effect. In addition, podofilox is known to interfere with nucleoside transport, which may also contribute to its action. Adverse effects reported in less than 5% of the patients included pain with intercourse, insomnia, tingling, bleeding, tenderness, chafing, malodor, dizziness, scarring, vesicle formation, crusting edema, dryness/peeling, foreskin irretraction, hematuria, vomiting and ulceration.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095182 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2011590 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CONDYLOX Approved UsePodofilox Topical Solution 0.5% is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts (see PRECAUTIONS ). Diagnosis Although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma (so-called Bowenoid papulosis) is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with Podofilox Topical Solution 0.5%. Launch Date6.6104643E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
17 ng/mL DRUG LABEL https://www.drugs.com/pro/podofilox.html |
1.5 mL single, topical dose: 1.5 mL route of administration: Topical experiment type: SINGLE co-administered: |
PODOFILOX plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.5 h DRUG LABEL https://www.drugs.com/pro/podofilox.html |
1.5 mL single, topical dose: 1.5 mL route of administration: Topical experiment type: SINGLE co-administered: |
PODOFILOX plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 26 Health Status: unhealthy Condition: Perianal warts Age Group: adult Sex: F Population Size: 26 Sources: |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (79.2%) Sources: Pain (79.2%) Itching (83.3%) Bleeding (45.8%) |
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 82 Health Status: unhealthy Condition: External genital warts Age Group: adult Sex: F Population Size: 82 Sources: |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (49.4%) Sources: Pain (54.3%) Itching (59.3%) Bleeding (29.6%) |
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 86 Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sex: F Population Size: 86 Sources: |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (52.3%) Sources: Pain (55.8%) Itching (60.5%) Bleeding (32.6%) |
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 119 Health Status: unhealthy Condition: External genital warts Age Group: adult Sex: M Population Size: 119 Sources: |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (83.2%) Sources: Pain (49.6%) Itching (52.9%) Bleeding (28.6%) |
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 127 Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sex: M Population Size: 127 Sources: |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (81.9%) Sources: Pain (50.4%) Itching (52.8%) Bleeding (26.8%) |
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 14 Health Status: unhealthy Condition: Perianal warts Age Group: adult Sex: M Population Size: 14 Sources: |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (71.4%) Sources: Pain (71.4%) Itching (57.1%) |
0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Other AEs: Inflammation, Pain... Other AEs: Inflammation (mild, 32.2%) Sources: Pain (mild, 23.7%) Itching (mild, 32.2%) Bleeding (mild, 19.2%) Inflammation (moderate, 30.4%) Pain (moderate, 20.4%) Itching (moderate, 16%) Bleeding (moderate, 3%) Inflammation (severe, 9.3%) Pain (severe, 11.5%) Itching (severe, 7.8%) Bleeding (severe, 0.7%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Bleeding | 45.8% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 26 Health Status: unhealthy Condition: Perianal warts Age Group: adult Sex: F Population Size: 26 Sources: |
Inflammation | 79.2% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 26 Health Status: unhealthy Condition: Perianal warts Age Group: adult Sex: F Population Size: 26 Sources: |
Pain | 79.2% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 26 Health Status: unhealthy Condition: Perianal warts Age Group: adult Sex: F Population Size: 26 Sources: |
Itching | 83.3% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 26 Health Status: unhealthy Condition: Perianal warts Age Group: adult Sex: F Population Size: 26 Sources: |
Bleeding | 29.6% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 82 Health Status: unhealthy Condition: External genital warts Age Group: adult Sex: F Population Size: 82 Sources: |
Inflammation | 49.4% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 82 Health Status: unhealthy Condition: External genital warts Age Group: adult Sex: F Population Size: 82 Sources: |
Pain | 54.3% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 82 Health Status: unhealthy Condition: External genital warts Age Group: adult Sex: F Population Size: 82 Sources: |
Itching | 59.3% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 82 Health Status: unhealthy Condition: External genital warts Age Group: adult Sex: F Population Size: 82 Sources: |
Bleeding | 32.6% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 86 Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sex: F Population Size: 86 Sources: |
Inflammation | 52.3% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 86 Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sex: F Population Size: 86 Sources: |
Pain | 55.8% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 86 Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sex: F Population Size: 86 Sources: |
Itching | 60.5% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 86 Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sex: F Population Size: 86 Sources: |
Bleeding | 28.6% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 119 Health Status: unhealthy Condition: External genital warts Age Group: adult Sex: M Population Size: 119 Sources: |
Pain | 49.6% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 119 Health Status: unhealthy Condition: External genital warts Age Group: adult Sex: M Population Size: 119 Sources: |
Itching | 52.9% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 119 Health Status: unhealthy Condition: External genital warts Age Group: adult Sex: M Population Size: 119 Sources: |
Inflammation | 83.2% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 119 Health Status: unhealthy Condition: External genital warts Age Group: adult Sex: M Population Size: 119 Sources: |
Bleeding | 26.8% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 127 Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sex: M Population Size: 127 Sources: |
Pain | 50.4% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 127 Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sex: M Population Size: 127 Sources: |
Itching | 52.8% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 127 Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sex: M Population Size: 127 Sources: |
Inflammation | 81.9% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 127 Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sex: M Population Size: 127 Sources: |
Itching | 57.1% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 14 Health Status: unhealthy Condition: Perianal warts Age Group: adult Sex: M Population Size: 14 Sources: |
Inflammation | 71.4% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 14 Health Status: unhealthy Condition: Perianal warts Age Group: adult Sex: M Population Size: 14 Sources: |
Pain | 71.4% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult n = 14 Health Status: unhealthy Condition: Perianal warts Age Group: adult Sex: M Population Size: 14 Sources: |
Bleeding | mild, 19.2% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Pain | mild, 23.7% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Inflammation | mild, 32.2% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Itching | mild, 32.2% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Itching | moderate, 16% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Pain | moderate, 20.4% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Bleeding | moderate, 3% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Inflammation | moderate, 30.4% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Bleeding | severe, 0.7% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Pain | severe, 11.5% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Itching | severe, 7.8% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Inflammation | severe, 9.3% | 0.5 % 2 times / day multiple, topical Recommended Dose: 0.5 %, 2 times / day Route: topical Route: multiple Dose: 0.5 %, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: Anogenital warts Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
yes [IC50 1.1 uM] | ||||
yes [IC50 4.6 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/29678463/ |
yes | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/29678463/ |
yes | |||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Sensory neuropathy due to Bajiaolian (Podophyllotoxin) intoxication. | 2000 |
|
TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. | 2000 Aug 1 |
|
Enhanced podophyllotoxin production from Agrobacterium rhizogenes transformed cultures of Podophyllum hexandrum. | 2001 |
|
Issues and practicalities of treating genital warts in the community. Proceedings of a round table meeting facilitated by Succinct Communications Limited. | 2001 |
|
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease. | 2001 Apr |
|
A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. | 2001 Apr 20 |
|
Secoisolariciresinol dehydrogenase purification, cloning, and functional expression. Implications for human health protection. | 2001 Apr 20 |
|
The successful treatment of molluscum contagiosum with podophyllotoxin (0.5%) self-application. | 2001 Dec |
|
A fast and simple GC MS method for lignan profiling in Anthriscus sylvestris and biosynthetically related Plant species. | 2001 Dec |
|
Podophyllin office therapy against condyloma should be abandoned. | 2001 Dec |
|
High yield of podophyllotoxin from leaves of Podophyllum peltatum by in situ conversion of podophyllotoxin 4- O-beta-D-glucopyranoside. | 2001 Feb |
|
[Clinical aspects and therapy of anogenital warts and papillomavirus-associated lesions]. | 2001 Jan |
|
GATA-4 and serum response factor regulate transcription of the muscle-specific carnitine palmitoyltransferase I beta in rat heart. | 2001 Jan 12 |
|
Cytotoxic responses to aromatic ring and configurational variations in alpha-conidendrin, podophyllotoxin, and sikkimotoxin derivatives. | 2001 Jan 18 |
|
[PAPP-A in the first trimester of pregnancy]. | 2001 Jul |
|
TNF-alpha downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding. | 2001 Jun |
|
The production of cytotoxic lignans by plant cell cultures. | 2001 Mar |
|
Direct medical costs for surgical and medical treatment of condylomata acuminata. | 2001 Mar |
|
Contact dermatitis from topical antiviral drugs. | 2001 May |
|
A pancreatic beta -cell-specific enhancer in the human PDX-1 gene is regulated by hepatocyte nuclear factor 3beta (HNF-3beta ), HNF-1alpha, and SPs transcription factors. | 2001 May 18 |
|
Analytical approaches for traditional chinese medicines exhibiting antineoplastic activity. | 2001 Nov 25 |
|
Management of anogenital warts (condylomata acuminata). | 2001 Nov-Dec |
|
Second malignancy after treatment of childhood non-Hodgkin lymphoma. | 2001 Oct 1 |
|
[Myelotoxicity of a plant cytostatic preparation etoposide]. | 2001 Sep-Oct |
|
Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream. | 2001 Sep-Oct |
|
Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia. | 2002 |
|
Clinical inquiries. What is the most effective treatment for external genital warts? | 2002 Apr |
|
Antitumor and antioxidant activity of spin labeled derivatives of podophyllotoxin (GP-1) and congeners. | 2002 Apr 5 |
|
Biological activity of 4-acetyltropolone, the minor component of Thujopsis dolabrata SIeb. et Zucc. hondai Mak. | 2002 Aug |
|
[Incidence and management of condylomata acuminata by French general physicians]. | 2002 Aug-Sep |
|
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. | 2002 Dec 15 |
|
Prodrugs of 4'-demethyl-4-deoxypodophyllotoxin: synthesis and evaluation of the antitumor activity. | 2002 Dec 2 |
|
Human T-cell leukemia virus type I Tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness. | 2002 Feb 15 |
|
Differential modulation by estradiol of P-glycoprotein drug resistance protein expression in cultured MCF7 and T47D breast cancer cells. | 2002 Jul-Aug |
|
Flow cytometric estimation on cytotoxic activity of leaf extracts from seashore plants in subtropical Japan: isolation, quantification and cytotoxic action of (-)-deoxypodophyllotoxin. | 2002 Jun |
|
Methamphetamine activates DNA binding of specific redox-responsive transcription factors in mouse brain. | 2002 Oct 1 |
|
A multicomponent reaction for the one-pot synthesis of 4-aza-2,3-didehydropodophyllotoxin and derivatives. | 2002 Sep 19 |
|
Synthesis and cytotoxicity of podophyllotoxin analogues modified in the A ring. | 2003 Jan |
|
[Bacteremia due to Capnocytophaga spp.: two cases]. | 2003 Mar |
Sample Use Guides
Apply twice daily morning and evening (every 12 hours), for 3 consecutive days, then withhold use for 4 consecutive days. This 1 week cycle of treatment may be repeated up to four times until there is no visible wart tissue. Podofilox 0.5% solution is applied to the warts with a cotton-tipped applicator supplied with the drug. The drug-dampened applicator should be touched to the wart to be treated, applying the minimum amount of solution necessary to cover the lesion. Treatment should be limited to less than 10 cm2 of wart tissue and to no more than 0.5 mL of the solution per day.
Route of Administration:
Vaginal
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000008732
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
||
|
NCI_THESAURUS |
C67421
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
||
|
WHO-ATC |
D06BB04
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
||
|
WHO-VATC |
QD06BB04
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10607
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | |||
|
7238
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | |||
|
SUB14925MIG
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | |||
|
8463
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | RxNorm | ||
|
M8933
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | Merck Index | ||
|
CHEMBL61
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | |||
|
518-28-5
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | |||
|
L36H50F353
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | |||
|
C29368
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | |||
|
PODOPHYLLOTOXIN
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | |||
|
3481
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | |||
|
D011034
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | |||
|
208-250-4
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | |||
|
518-28-5
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY | |||
|
DB01179
Created by
admin on Fri Jun 25 21:08:40 UTC 2021 , Edited by admin on Fri Jun 25 21:08:40 UTC 2021
|
PRIMARY |
ACTIVE MOIETY